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OBJECTIVES: This study aimed to determine the budget impact of adding turocto-
cog alfa to a U.S. health plan insurer’s formulary for the treatment of hemophilia 
A. METHODS: A budget impact model was developed to evaluate factor replacement 
therapy costs, for patients with hemophilia A (without inhibitors), from the perspec-
tive of a US managed care plan. Key model inputs included benefit plan characteris-
tics (i.e. number of members and time frame of the model), patient characteristics 
(i.e. number of pediatric and adult patients; mean weight), treatment characteristics 
(i.e. prophylaxis, on-demand, or perioperative treatment), and disease outcomes 
(i.e. annual bleed rate, severity level of bleeding episode, bleed control, and major 
surgery). The model compared treatment with turoctocog alfa versus marketed 
recombinant and plasma-derived FVIII alternatives. For children and adults, base 
case weight-based dosage and frequency for prophylaxis was assumed to follow 
the Malmö Protocol, whereas on-demand and perioperative dosages were based on 
respective product package inserts. Market share was indexed at Year 1. All costs 
were based on estimated WAC drug costs (US dollars), and product information 
current as of January 15, 2015. RESULTS: For a hypothetical managed care plan 
with 1,000,000 members, the estimated number of hemophilia A patients was 39, 
based on US prevalence data. Assuming proportional adoption of turoctocog alfa 
from all branded rFVIII and plasma-derived FVIII, total annual treatment costs were 
$10,133,595 without turoctocog alfa and $10,138,671 with turoctocog alfa, resulting 
in a budget impact of $5,076 or $0.00042 per member per month (PMPM). Results 
were sensitive to prevalence of hemophilia A, drug cost, proportion of patients 
on prophylaxis, and proportion of major bleeding episodes for patients treated 
on-demand, based on one-way sensitivity analyses. CONCLUSIONS: Inclusion of 
turoctocog alfa on a formulary provides a budget neutral treatment option, having 
a negligible budget impact on the annual pharmacy budget.
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OBJECTIVES: To estimate the budget impact of adding rFVIIIFc to a managed care 
organization (MCO) formulary in the United States METHODS: A model was devel-
oped in Microsoft® Excel 2010 to evaluate the budget impact of including rFVIIIFc on 
formularies along with other recombinant FVIII (rFVIII) therapies over a 2-year time 
horizon. The model compared the drug-related costs of an MCO formulary contain-
ing conventional FVIII treatments with the costs of a formulary that also includes 
rFVIIIFc. The number of people with hemophilia A in the MCO was estimated using 
published prevalence data and was limited to adults with severe hemophilia A, 
free from FVIII inhibitors (neutralizing antibodies), receiving treatment with rFVIII 
therapy. It was assumed that 55% of patients receive prophylaxis therapy while 
the remaining 45% receive episodic therapy. Market share of rFVIIIFc was assumed 
to increase from 0% to 8.5% in year 1 and year 2. Medication costs were the only 
resource included in the budget impact model. The annual costs associated with 
factor replacement therapy were estimated by factor unit costs (acquisition cost) 
and by annual factor consumption. Annual factor consumption and bleeding rates 
were estimated using clinical trial and real world data. RESULTS: The estimated 
budget impact of adding rFVIIIFc to the formulary was associated with a budget 
increase of 1.4%/year for a private payer population of 1,000,000 plan members, with 
an estimated 21 members receiving treatment for hemophilia A. The overall impact 
to the budget was estimated to be $121,176 per year which corresponds to $0.01 per 
member per month, largely due to patients switching from episodic to prophylaxis 
therapy. Switching to rFVIIIFc therapy was projected to reduce the annual bleed rate 
by approximately 3.1 bleeds/patient/year, with an incremental cost of $1,880 per 
bleed avoided. CONCLUSIONS: Introduction of rFVIIIFc into MCO formularies may 
be associated with minimal budget impact.
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OBJECTIVES: Growing emphasis on cost containment in healthcare means that hos-
pitals must develop strategies to minimize adverse clinical outcomes while increas-
ing cost efficiency. A propensity-matched retrospective analysis of SIRS patients 
from a large US electronic health record (EHR) database identified significantly 
reduced odds of serious complications, when IV fluid therapy was predominantly 
with BAL versus 0.9% saline.[1]This analysis evaluates the economic implication 
of increasing usage of BAL for IV fluid therapy in SIRS patients from a US hospital 
perspective. Impact of Intravenous Fluid Composition on Outcomes in Patients with 
the Systemic Inflammatory Response Syndrome Andrew D. Shaw; Carol R. Schermer, 
Dileep N. Lobo, Sibyl H. Munson, Victor Khangulov, David Hayashida, and John A. 
Kellum: submitted for publication. METHODS: A budget impact model (BIM) was 
developed to assess the impact of increased usage of BAL in SIRS patients. Model 
parameters combined clinical inputs derived from the retrospective EHR analysis 
with fluid costs and complication-associated costs obtained from published reports 
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OBJECTIVES: The current study examined chronic pain prevalence in the U.S. 
Veterans Health Administration (VHA) population. METHODS: The study sample 
was based on the VHA Medical SAS Datasets from fiscal year 2008 through 2012. All 
patients diagnosed with chronic pain throughout the study period were identified 
using International Classification of Diseases, 9th Revision, Clinical Modification 
diagnosis codes 338.2 and 338.4. The variation in the prevalence of chronic pain 
was assessed and categorized according to the pain scale. Pain score was deter-
mined using a scale ranging from 0 to 10 as reported by patients using the follow-
ing categories: 1 to 4: mild, 5 to 6: moderate and ≥ 7: severe pain. To identify prior 
prevalence cases, we restricted continuous enrollment throughout that fiscal year 
and at least 2 years prior. RESULTS: In 2008, patients aged 45-64 had the highest 
percentage of patients with mild (56.4 %), moderate (60.7%) and severe (65.4%) 
pain. This trend was found for all study years. In 2008, white patients had the 
highest prevalence of mild (64.29%), moderate (62.07%) and severe (59.06%) pain. 
Similarly, in 2008, patients who resided in the South U.S. region had the highest 
prevalence of mild (32.89%), moderate (33.68%) and severe (36.39%) pain compared 
to other regions. This trend continued through all study years. Utah had the high-
est prevalence of chronic pain in 2008 (4.9%) and 2012 (24.0%). CONCLUSIONS: 
Among VHA beneficiaries with chronic pain, patients who were age 45-64 years 
had the highest prevalence of chronic pain. Also, white patients and those 
who resided in the South U.S. region had the highest prevalence of chronic 
pain.
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OBJECTIVES: An estimated 100 million adult Americans suffer from chronic 
pain. Prescribing opioids remains a primary treatment option for physicians. 
Hydrocodone/acetaminophen (HC/APAP) is the most commonly prescribed opioid 
in the US. However, the FDA recently rescheduled HC/APAP from Schedule III to II, 
due to negative outcomes, including its association with emergency department 
(ED) visits. The objective of this study was to estimate the impact of HC/APAP use 
in Texas on ED visits, based on the prevalence of HC/APAP prescriptions within the 
state. METHODS: A retrospective cohort design used data from the Drug Abuse 
Warning Network (DAWN) on ED visits associated with HC/APAP. Additionally, data 
from the Texas prescription drug monitoring program (PDMP) with patient level 
information for all Schedule II to V drugs dispensed within the state for a 12 month 
period was used to assess the prevalence of patients taking HC/APAP. This analysis 
yielded estimates of potential ED visits related to HC/APAP within Texas. RESULTS: 
National estimates from DAWN reveal that ED visits related to HC/APAP increased 
from 23.6 per 100,000 population in 2004 to 50.2 per 100,000 population in 2011. Data 
from the Texas PDMP contained 39,904,964 distinct prescriptions for all Schedule 
II to V controlled substances for the period from June 2013 to May 2014 within the 
state of Texas. CONCLUSIONS: The use of HC/APAP requires more active moni-
toring in order to reduce the number of ED visits associated with its use. Future 
studies should investigate whether rescheduling HC/APAP leads to reduction of 
related ED visits.
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OBJECTIVES: This study examined mortality risk among patients with psoriasis 
in the United States. METHODS: MarketScan databases were linked to the Social 
Security Administration death file to select adults with ≥ 1 inpatient or ≥ 2 outpa-
tient diagnoses of psoriasis (ICD-9-CM 696.1x) during the study period (1/1/2006 to 
6/30/2014). The first psoriasis diagnosis was the index date. Patients had 6 months 
of pre index continuous enrollment and were followed until the earliest of death or 
end of the study period. Comorbidities during the pre-index period were examined. 
Mortality incidence was calculated for psoriasis patients by comorbidities and age 
group. A Cox proportional hazards model was used to identify predictors of mortal-
ity. RESULTS: The sample comprised 102,573 psoriasis patients with mean age of 
52.7 years (yrs). Patients were followed for an average of 4.9 yrs and 3.4% died dur-
ing the study period. The mean age at death was 75.5 yrs. The mortality rate was 7.0 
per 1,000 person-years (PY) and increased with age (0.8 per 1,000 PY in patients aged 
18-24 yrs versus 45.5 per 1,000 PY in patients ≥ 75 yrs). The mortality rate was sig-
nificantly higher for psoriasis patients with (versus without) diabetes (17.5 vs. 5.7), 
hypertension (12.6 vs. 4.8), coronary heart disease (24.9 vs. 5.4), cerebrovascular 
disease (31.9 vs. 6.2), and peripheral vascular disease (36.8 vs. 6.1) (all p< 0.05). 
Multivariate analysis suggested that older age, female gender, higher Charlson 
Comorbidity Index (CCI) score, and presence of comorbidities (diabetes, coro-
nary heart disease, cerebrovascular disease, peripheral vascular disease, and 
malignancy) were associated with increased risk of mortality amongst pso-
riasis patients (all p< 0.001). CONCLUSIONS: Among patients with psoriasis, 
the rate of mortality was 7.0 per 1,000 person-years. Diabetes, cardiovascu-
lar diseases, malignancy, female gender, older age, and increased CCI scores 
were associated with an elevated risk of mortality in this cohort of psoriasis 
patients.
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We performed a cost analysis of voriconazole versus caspofungin as first-line 
antifungal treatment for IA among patients with prolonged neutropenia or 
undergoing bone marrow or hematopoietic stem-cell transplantation (BMT/
HSCT) from a Chinese hospital perspective. METHODS: A decision analytic 
model with a 30-day time horizon was constructed to estimate the potential 
treatment costs of alternative interventions voriconazole versus caspofungin. 
Each pathway in the model was defined by probabilities of an event to occur and 
costs of clinical outcomes. Outcome probabilities and cost inputs (in 2014 RMB 
Yuan) were derived from published literature, clinical trials, and recommenda-
tions from expert panels. In the base case, patients who failed first-line therapy 
were assumed to either experience a single switch between study drugs or add 
on the other study drug as second-line treatment options. Base-case evaluation 
included drug management costs and additional hospitalization costs due to 
severe adverse events. RESULTS: Based on clinical trial treatment success rates 
of 52.8% (voriconazole) and 33.0% (caspofungin), and LOT= 15-day -IV + 15-day 
oral for voriconazole and 30-day IV for caspofungin, voriconazole had a lower 
total treatment cost than caspofungin (¥58,514 vs ¥67,822) despite its higher drug 
cost. Cost savings were primarily due to the higher treatment efficacy and shorter 
IV LOT associated with voriconazole. LOT and drug prices were the main cost 
drivers. The cost advantage of voriconazole persists with up to 19 days of IV treat-
ment with a proportional decrease in oral treatment to11 days. CONCLUSIONS: 
This study suggests that voriconazole is likely to be cost-saving compared to 
caspofungin in the treatment of invasive aspergillosis from the Chinese hospital 
perspective.
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OBJECTIVES: When selecting postoperative pain management (POPM) for an 
individual patient, clinicians weigh the analgesic efficacy, risk of adverse events, 
and any additional resource consumption associated with the administration 
of treatment. This analysis estimated the total cost and resource use associated 
with utilizing fentanyl iontophoretic transdermal system (ITS) versus standard 
intravenous patient-controlled analgesia (IV PCA) morphine for POPM. METHODS: 
A cost calculation model was developed to evaluate the economic value of fentanyl 
ITS compared to IV PCA morphine for a hospital performing inpatient orthopedic 
surgery. The model considered resource use and direct costs for opioid related 
adverse events (ORAEs), IV PCA medication/device errors, supplies, equipment, 
hospital staff time and drug for the management of postoperative pain. Model 
assumptions were informed by published literature, the PREMIER hospital data-
base, fentanyl ITS active-controlled trial data, and online sources. RESULTS: The 
orthopedic patient population included knee arthroplasty (Clinical Classification 
Software CCS= 152), total or partial hip replacement (CCS= 153) laminectomy with 
excision intervertebral disc (CCS= 3), or spinal fusion (CCS= 158). The duration of 
pain management modeled was 48 hours. Fentanyl ITS use reduced the per-
patient costs associated with ORAEs by $402, IV PCA medication/device errors by 
$29, and the direct costs of supplies and equipment by $98. Fentanyl ITS reduced 
RN/LPN time associated with PCA administration tasks by 38% and eliminated 
tasks performed by the pharmacy, central supply and bioengineering staff for 
a savings of $35. CONCLUSIONS: Within the hospital setting, this analysis cal-
culates fentanyl ITS may reduce the economic burden associated with ORAEs, 
pump and programming errors, labor and supply/equipment costs compared to IV 
PCA, resulting in a potential economic benefit of $579 per patient over a 48-hour 
period.
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OBJECTIVES: When making reimbursement decisions, policy-makers in China 
need to consider the economic impact of the treatment, which is determined by 
both epidemiological factors and treatment costs. In this study, we compare the 
total annual budget impact of different diseases of various treatment costs and 
prevalence rates. METHODS: We considered six diseases in our analysis: hemo-
philia B, HIV, hypertension, non-small cell lung cancer (NSCLC), tuberculosis, 
and type 2 diabetes mellitus (T2DM). These choices provided a sample of highly 
prevalent diseases (hypertension) and rare diseases (hemophilia B) as well as 
high cost (NSCLC) and low cost (type 2 diabetes) treatments. The budget impact 
was calculated by multiplying the number of patients by the cost per patient. The 
data sources for prevalence and cost were obtained using a search of previously 
published literature with the following criteria: in English, with abstract, published 
within the past ten years. All costs were converted to USD using (1 USD = 6.07 
RMB). RESULTS: China has a population of 1.3 billion, and the most common 
disease of our selection was hypertension (254 million) followed by T2DM (114 
million), HIV (1.4 million), tuberculosis (1.3 million), NSCLC (515,000), and hemo-
philia B (4,887). The annual per-patient-cost was highest for hemophilia B ($12,670) 
followed by NSCLC ($11,566), HIV ($2,242), tuberculosis ($724), hypertension ($367), 
and T2DM ($194). The budget impact was highest for hypertension ($93 billion) fol-
lowed by T2DM ($22 billion), NSCLC ($6 billion), HIV ($3 billion), tuberculosis ($900 
million), and hemophilia B ($62 million). CONCLUSIONS: When determining the 
economic impact of a treatment on a health system, payers need to consider both 
the cost of the treatment as well as the size of the patient population. Though a 
rare disease may have high cost of treatment, its budget impact is relatively small 
because of the population size.
and literature. Overall savings were calculated by subtracting the costs of compli-
cations and treatments associated with BAL adoption level for a given year from 
costs associated with current BAL adoption level and adding the incremental costs. 
Scenario analyses examined cost impacts for hospitals of various sizes, with differ-
ent BAL adoption levels and rates. RESULTS: Base case scenario analysis showed 
year 1 hospital savings of $69,846 (USD) and 5-year cumulative savings of $2.77M. 
At the pharmacy level, despite higher fluid costs, estimated savings were $9,836 
in the first year and $389,262 over 5 years. Alternate scenario analyses involving 
larger hospital size, year 5 BAL usage in greater proportions of patients and rapid/
early BAL adoption demonstrated increased cumulative savings over the 5 year 
period. CONCLUSIONS: Increased BAL usage represents an opportunity for US hos-
pitals and pharmacy departments to reduce complication-related costs associated 
with managing SIRS patients.
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OBJECTIVES: Current practice guidelines in Scotland recommend pregabalin in 
primary care if first- and second-line treatments (amitriptyline or gabapentin) 
are ineffective or poorly tolerated. Capsaicin 8% patch (QUTENZA™) is currently 
used as an add-on to pregabalin and only within a specialist setting. Scottish 
prescribers have made two suggestions to improve current care; first, using cap-
saicin 8% patch instead of pregabalin following failure of initial treatments; and 
second, administering capsaicin 8% patch within primary care. We built a model to 
evaluate the potential budget impact from implementing the suggested treatment 
practices. METHODS: The model assessed a hypothetical cohort of 100 patients 
with non-diabetic PNP, treated by a primary care physician, a pain specialist or 
both (integrated care). Two patient cohorts were modelled: pregabalin-naïve (i.e. 
previously untreated with) or pregabalin-treated. Costs were estimated for the 
base-case scenarios (secondary care use of pregabalin only for pregabalin-naïve 
and -treated patients) and new treatment pathways (replacing pregabalin with 
capsaicin 8% patch). Model input values included 150mg daily dose of prega-
balin and capsaicin 8% patches (1.45 patches/patient; 5.25 months retreatment 
time). RESULTS: In the base-case scenario for pregabalin-naïve patients, the esti-
mated cost (per 100 patients) was £82,800. The estimated costs of introducing 
capsaicin 8% patch were £92,686 (£9886 difference) in secondary care, £86,743 
(£3943) in primary care and £89,343 (£6543) in integrated care. In pregabalin-treated 
patients, the estimated base-case scenario cost was £185,200. The estimated costs 
of introducing capsaicin 8% patch were £175,486 (–£9714 difference) in secondary 
care, £169,543 (–£15,657) in primary care and £172,143 (–£13,057) in integrated 
care. CONCLUSIONS: Replacing pregabalin with capsaicin 8% patch in pregabalin-
naïve patients was associated with cost savings within primary and integrated 
care compared with secondary care. Additionally, cost savings versus pregabalin 
were observed with capsaicin 8% patch in pregabalin-treated patients within all 
three treatment pathways.
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OBJECTIVES: Payers may grant coverage for bariatric surgery (BaS) for patients with 
BMI ≥ 40 or BMI 35-39.9 with ≥ 1 obesity-related comorbidities. Trial of weight loss 
(WL) medications before BaS may be beneficial to both payers and patients if some 
patients can avoid BaS. This analysis evaluated the cost impact of lorcaserin, a 
FDA- approved WL medication, in weight management prior to BaS from payer’s 
perspective. METHODS: Cost impact of lorcaserin for WL prior to BaS was assessed 
in a hypothetical US health plan of one million members over a 2-year horizon. Key 
assumptions include: 1) Average cost per BaS is $29,517; 2) Patients with BMI reduced 
to below 35 with pre-BaS WL can avoid BaS; 3) Only BaS and lorcaserin drug costs are 
included; 4) Only patients who achieve ≥ 5% weight loss at week 12 continue lorca-
serin treatment (WK-12 responders). For modeling purpose, WL data for lorcaserin 
were drawn from a subset of patients in three clinical trials (BLOSSOM, BLOOM, 
BLOOM-DM) evaluating the efficacy and safety of lorcaserin for WL. RESULTS: 42.5% 
of patients with baseline BMI≥ 40 were WK-12 responders (average BMI 42.3) and 
17.6% of them reduced BMI to below 35 at one year with lorcaserin treatment. In 
patients with baseline BMI 35-39.9 and ≥ 1 obesity-related comorbidities, 49.3% were 
WK-12 responders (average BMI 37.2), and 72.6% of them reduced BMI to below 35 
at one year with lorcaserin treatment. The cost analysis estimated cumulative sav-
ing of $1,033,407 over 2 years if patients who reduced their BMI to below 35 with 
lorcaserin can avoid BaS. CONCLUSIONS: From payer’s perspective, using lorcaserin 
for WL prior to BaS may lead to significant cost saving over a 2-year horizon. Real 
world, long-term evidence is needed for further evaluation of the role of lorcaserin 
for weight management in patients considering BaS.
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OBJECTIVES: Published real-world studies suggested voriconazole (Vfend) may 
provide reduced length-of-stay, intravenous (IV) length-of-therapy (LOT), and 
costs compared to caspofungin (Cancidas) in invasive aspergillosis (IA) patients. 
